

AMP  **GERMAN
CANNABIS
GROUP**

Formerly Chinook Tye Industry Limited



AMP-EU.com

Q3
2019

CSE: XCX | FSE: C4T | ISIN: CA00176G1028

Safe Harbour

This Presentation contains “forward-looking information” within the meaning of applicable Canadian securities legislation which are based upon the Company’s current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy.

Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information in this Presentation is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances as at the date hereof. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. In particular, we have made assumptions in respect to our competitive advantages; the expected legalization of cannabis use in Canada; the growth of our business and expansion into new markets; the development of new products and product formats for our cannabis-based pharmaceutical products; our ability to retain key personnel; our ability to continue investing in our infrastructure to support our growth; our ability to obtain and maintain financing on acceptable terms; the impact of competition; the changes and trends in the medical cannabis industry; and changes in laws, rules and regulations.

Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that we considered appropriate and reasonable as of the date hereof, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual actions, events, results, performance or achievements to differ materially from what is projected in forward-looking information, including but not limited to the risks described in greater detail in the section entitled “Risk Factors” in our most recent annual information form available on SEDAR at www.sedar.com.

Although we have attempted to identify important factors that could cause actual actions, events, results, performance or achievements to differ materially from those described in forward-looking information, there may be other factors not presently known to us or that we presently believe are not material that may cause actions, events, results, performance or achievements to differ from those anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking information prove incorrect, actual actions, events, results, performance or achievements may vary materially from those expressed and implied by such statements contained in this Presentation. The purpose of forward-looking information is to provide the reader with a description of management’s expectations, and such statements may not be appropriate for any other purpose. Accordingly, readers should not place undue reliance on forward-looking information. Although the Company believes that the expectations reflected in statements containing forward-looking information are reasonable, it can give no assurance that such expectations will prove to be correct. The Company disclaims any obligation to update any forward-looking information, whether as a result of new information or future events or results, except to the extent required by applicable securities laws.




Germany Trusts Canada

Germany sales of medical cannabis were higher than all the other European countries combined, representing the most important cannabis market outside North America.

Canada is a reliable supplier

Canada will become the largest exporter of EU-GMP cannabis to Germany and EU due to its decade experience of government oversight in the development of its medical cannabis industry.

Due to high pharmaceutical quality and regional government certification requirements,¹ three Canadian² and one Dutch³ company supply the German medical cannabis market.



Dutch have lost their first mover advantage

Restricted exports outside the Netherlands limits the Dutch's future role as a supplier to Germany and Europe.



Denmark, Australia, Israel and others are late-comers

Latecomers will take years to catch up to the regulatory standards of the Canadian industry. Until then, Canada will enjoy its competitive lead.

German cultivation will not meet demand

Germany recently issued licences to three Canadian companies⁴ to cultivate a maximum of 2,600 kilograms annually for four years, which will be a small part of the market until Germany issues more cultivation licences.

Germany is fully dependent on imports for the foreseeable future.


Footnotes

- (1) See slide 6.
- (2) Canopy Growth (NYSE: CGC), Aurora (NYSE: ACB) and Cronos Group (Nasdaq: CRON).
- (3) Bedrocan.
- (4) Aphria (NYSE: APHA), Aurora and Demecan GmbH/Wayland Group (CSE: WAYL).

AMP strategy is to be a significant supplier to the German market

AMP German Cannabis Group (AMP) invests in businesses that supply the German medical cannabis industry through its subsidiaries:

-  **AMP Germany** purchases and imports EU-GMP cannabis from licensed producers (LP) in Canada to Germany. LPs that AMP Germany enter into supply agreements go through *The AMP EU-GMP Certification Protocol* to ensure the LPs will meet the high quality and consistency standards required to export to Germany.
-  **AMP Switzerland** develops sources of EU-GMP CBD cannabis for export to Germany once applicable laws permit such transactions. It is legal to cultivate CBD cannabis with THC <1.0% in Switzerland.
-  **AMP Malta** will source and develop EU-GMP cannabis cultivated or imported into Malta for export to Germany. Malta is the only EU country to allow unrestricted exports of medical cannabis to other EU countries.





Canada will be the biggest exporter to Germany and Europe

Canada became the second largest supplier of EU-GMP cannabis to Germany after legalization at the expense of the Dutch.

Canada's success in Germany resulted in it becoming the second largest supplier to Europe as only Canada can meet the European pharmaceutical standards.

German sales of EU-GMP cannabis by country in 2017 (8 months) and 2018⁸

European sales of EU-GMP cannabis by country in 2017 and 2018⁸



Footnotes

(8) Source data: 2019 Marijuana Business Daily Report: Medical Cannabis in Europe, The Market & Opportunities.

AMP EU-GMP Certification Protocol

AMP provides a complete solution for Canadian medical cannabis cultivators to address the biggest obstacles entering the Germany market.

How AMP EU-GMP Certification Protocol Works

1. Upon AMP entering into a supply arrangement with a cultivators, AMP and its German business partners provide EU-GMP gap analysis, audit and certification and related services.
2. AMP will evaluate and confirm that cannabis produced by the cultivator meets EU-GMP regulations for importation into Germany.
3. Once a cultivator passes an audit, AMP arranges for EU-GMP inspection and certification by state authorities in Germany that issue the necessary import permits and certify foreign producers to export to Germany.
4. After the cultivator has obtained EU-GMP certification, AMP and the cultivator arrange for the necessary permits to import cannabis into Germany.

AMP's competitive advantage is ensuring Canadian cultivators will be able to begin sell to Germany quickly.



European Union - Good Manufacturing Practices (EU-GMP)

EU-GMP certification is an internationally recognized system that ensures that pharmaceutical goods, including medical cannabis, meet the highest consumer health and safety standards.



German EU-GMP

All medical cannabis imported into or produced in Germany are regulated by EU-GMP and must be certified by a German state.



Canadian Standards (GPP)¹

Canadian cannabis production and operating standards do not meet EU-GMP standards and need to be upgraded in order to receive EU-GMP certification from a German state..

Footnotes

(1) Good Production Practices (GPP) is the standard Canadian guidance that LP follow.

Share Metrics

AMP's market capitalization is \$6-million of which \$1-million is cash.

TSXV share price	\$ 0.32
TSXV 52-week share price high-low	\$ 0.45 to \$0.07
Market capitalization	\$ 6,100,000
Shares outstanding	20,217,796
Finder warrants ⁽¹⁾	240,228
Stock options ⁽²⁾	1,020,000
Shares outstanding fully diluted	21,478,024

Footnotes

- (1) Finder Warrant is exercisable at a price of \$0.15 per share until December 12, 2019.
(2) Stock Option is exercisable at \$0.15 per share until May 8, 2020.



Shareholder	Shares	Percentage
Insiders and Management	6,801,692	34%
Float	13,416,104	66%



The Company's office is near Brandenburg Gate, Berlin Germany

Share Trading and News from May to August

AMP lists on the CSE and makes major investment in AMP Germany



Board of Directors and Management



Dr. Stefan Feuerstein

Director and President

- Experienced corporate director, operating and financial executive with knowledge in plastic formation facilities, aluminum rolling mills, biodiesel and solar projects in Germany and abroad.
- Formerly, Managing Director of IIC Industrial Investment Council GmbH, which was the investment promotion agency for the five Eastern German states plus Berlin, assisting and advising companies around the world on all matters regarding investment opportunities in Germany and financed by the German Federal Ministry of Economics;
- Managing Director of TLW Thüringer Landwirtschafts Forderungsgesellschaft, Erfurt, and the German State of Thuringia economic development company; and
- Director of a Nasdaq-listed specialty trade and structured finance bank.
- Has a Doctorate, Magna cum Laude, in Politics from Freie University and a Master's Degree in Business Administration from Technische Universität in Berlin, Germany. Attended a Post Graduate Program from the Sloan Business School at MIT Massachusetts Institute of Technology in Cambridge, Massachusetts, USA.



Mr. Alex Blodgett

Director & CEO

- Three decades of experience in investment banking in Canada, the USA, Europe and Asia.
- Served on Canadian and US public company boards and has had senior executive roles in several early-stage companies.
- Formerly, Partner with Gordon Capital Corporation, a Canadian investment and merchant banking company; and
- Vice President of Corporate Finance with Bankers Trust Company in New York, Dallas and Los Angeles, with emphasis on large-scale project financing and management leveraged buyouts.
- Director of BC Cancer Foundation.
- Graduated with a Bachelor of Arts (Economics) from Hobart College in Geneva, New York, USA.



Mr. Claudio Morandi

Director

- Three decades of experience in Swiss and cross border corporate finance, investment banking and mergers and acquisitions.
- Formerly, Senior Vice President of MFC Merchant Bank Ltd., a specialty trade and structured finance bank.
- Graduated as a Swiss banker and has a degree in Macro and Micro Economics from Imaka Management Institute in Zurich, Switzerland. Certified Restructuring and Turnaround Consultant and ESUG Specialist from the IfUS Institute for Corporate Restructuring and Development in Heidelberg, Germany.



Mr. Kenneth MacLeod

Director

- Three decades of experience in developing resource development in the USA, Canada, Philippines and the Democratic Republic of Congo.
- CEO and President of Sonoro Metal Corp., a TSXV listed mineral exploration and development company.

Contact Information



Scan to go to AMP's investor resource site for German and Canadian investors.

amp-eu.com

Canadian Investors

Phone: +236-833-1602

investor@amp-eu.com

German and EU Investors

investor@amp-eu.de



@AMP_Cannabis



AMP German Cannabis



AMP_Cannabis



@AMPGCG

Germany

Alfred-Hess-Straße 23
Erfurt 99094, Germany

Charlottenstrasse 59
Berlin 10117, Germany

Canada

224 West 5th Avenue
Vancouver, B.C., V5Y 1J4, Canada



Only pharmacists with a physician prescription can dispense medical cannabis in Germany.